Diagnostic Models for New Diabetes in Moderate to Severe COVID-19 Patients

Overview

This study identifies insulin resistance (IR) as a key driver of newly diagnosed diabetes mellitus (DM) in patients with moderate to severe COVID-19. It demonstrates that combining the triglyceride-glucose (TyG) index with body mass index (BMI) and inflammatory biomarkers improves diagnostic accuracy for new-onset DM in this population.

Background

Obesity and insulin resistance are established risk factors for type 2 diabetes mellitus (T2DM), and viral infections such as SARS-CoV-2 have been linked to new diagnoses of DM, especially in individuals with elevated BMI. COVID-19 induces a pro-inflammatory state, with cytokines like IL-6 associated with disease severity, but their role in newly diagnosed DM and IR remains underexplored. The TyG index has emerged as a practical surrogate marker for IR, offering advantages over traditional methods in resource-limited settings. Understanding the interplay between metabolic dysfunction and inflammation in COVID-19 is critical for early identification and management of new diabetes cases.

Data Highlights

A meta-analysis estimated a 16% prevalence and 1.6% incidence of newly diagnosed DM post-COVID-19 infection, with higher rates among hospitalized patients. The United States Veterans Affairs cohort showed increased risk of new DM and need for anti-hyperglycemic medications after COVID-19. Prior research demonstrated fasting plasma glucose predicts COVID-19 outcomes. The TyG index outperforms HOMA-IR in estimating insulin resistance without requiring insulin measurement, enhancing its clinical utility.

Key Findings

• Insulin resistance is a central mechanism driving newly diagnosed diabetes in COVID-19 patients.
• The triglyceride-glucose (TyG) index significantly improves prediction of new-onset DM, especially when combined with BMI and inflammatory cytokines.
• Elevated BMI strongly correlates with increased risk of newly diagnosed DM in COVID-19.
• Inflammatory markers such as IL-6 contribute to the pathogenesis of insulin resistance and new diabetes during COVID-19.
• The TyG index is a cost-effective, practical surrogate for insulin resistance suitable for use in low- and middle-income countries.
• Populations with heightened baseline inflammation and insulin resistance, such as Black Africans, may be at greater risk for severe COVID-19 and new diabetes.

Clinical Implications

Clinicians should monitor cardiometabolic parameters, including insulin resistance markers like the TyG index, in COVID-19 survivors, particularly those with elevated BMI. Integrating obesity management and inflammation control may reduce the risk of developing diabetes post-infection. The TyG index offers a feasible tool for early identification of at-risk patients in resource-limited settings, facilitating timely intervention.

Conclusion

This study underscores the importance of insulin resistance and inflammation in the development of newly diagnosed diabetes among COVID-19 patients. Utilizing accessible markers such as the TyG index alongside BMI and inflammatory biomarkers can enhance diagnostic accuracy and guide targeted management strategies.

References

1. Various Authors/Multiple Years -- Diagnostic Models for Identifying New Cases of Diabetes Mellitus in Patients with Moderate to Severe COVID-19